Details of the Drug
General Information of Drug (ID: DM6PQ5V)
Drug Name |
4-amino-N-(2-chlorophenyl)benzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
19837-85-5; 4-amino-N-(2-chlorophenyl)benzenesulfonamide; 4-amino-N-(2-chlorophenyl)benzene-1-sulfonamide; 4-Amino-N-(2-chloro-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(2-chlorophenyl)-; AC1MP5DG; AC1Q51WZ; SCHEMBL1970942; n1-2-chlorophenylsulphanilamide; CHEMBL227597; CTK4E2501; DTXSID20392191; XZQHDUUDKCHQIL-UHFFFAOYSA-N; MolPort-002-463-078; ZINC3885452; STL420385; BBL034801; AKOS000115492; NE25153; MCULE-7275329899; KB-289984; FT-0719132; N-(2-Chlorophenyl)-4-aminobenzenesulfonamide; EN300-02335
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 282.75 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||